EXCLUSIVE: Benzinga Interviews Mind Cure CEO Kelsey Ramsden with Updates on Latest Press Release

Image by: iStock

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

In an exclusive interview with Benzinga on Monday, Kelsey Ramsden, the CEO of Mind Cure Health Inc. MCURF, shared insight into Mind Cure’s press release on Nov. 4, 2021, and shed light on the potential the company is looking to unlock. 

Research into MDMA treatments for psychological illnesses is meeting with official acceptance as public firms enter the space. Enveric Biosciences Inc. ENVB recently bought MagicMed, a biotechnology company focused on creating a library of novel derivative molecules based on classic psychedelics. COMPASS Pathways Plc CMPS is a British mental health care company researching how psilocybin therapy could help people with treatment-resistant depression.

Speaking to the completed draft research protocol for the use of MDMA and psychotherapy, which are used to treat female sexual hypoactive desire disorder, Ramsden said “We have the protocol completed, and soon you’ll see us, as shown in our catalysts, applying for a pre-IND meeting with the FDA, and then as we understand it we’ll be heading into a phase-2 study.” 

Additionally, in March 2021, Mind Cure broke the news it was initiating chemical synthesis routes for fully synthetic ibogaine production. According to Ramsden, ibogaine, a naturally occurring psychoactive substance found in plants, is known for its effect on opiate withdrawal and opiate recovery. Speaking specifically to the updates on ibogaine production, Ramsden said “We’re the first, that we know of, that has a full synthetic ibogaine program, so driving that into some animal models and advancing that research, we should have product on the market in Q2 that would be available for researchers as well, so not only doing our own research, but also selling drug products to others.” 

Mind Cure’s digital platform update also came into focus during the interview, with Ramsden sharing information about potential and future accomplishments made possible after its recent discoveries. According to the press release from Mind Cure, the company released the MVP of its digital therapeutics technology, iSTRYM, into partner clinics throughout North America in August. The release also references Mind Cure’s plan to commence full commercial deployment to all its partner clinics early in 2022, with plans for expansion into the U.K. and Europe by the later half of Q4 in 2022. 

Two new novel programs from Mind Cure were also a point of consideration during the interview, and Ramsden provided context about development of the intellectual property (IP) that it feels has indications of merit. MC-106 and MC-808 are both candidate selection programs currently underway according to the press release, and although the overall information provided was semi limited, Ramsden did comment on updates being available in the second quarter of 2022, painting the picture for potential announcements. 

Ramsden rounded out the interview by commenting on Mind Cure’s future progress, saying: “Because of the number of programs we have ongoing, we have a fairly robust catalyst list coming over the next eight to ten months, on both sides of the program with the technology side and on the drug development side.”

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.

Market News and Data brought to you by Benzinga APIs
Posted In: CannabisPenny StocksHealth CareSmall CapMarketsGeneralMind Cure
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

The Top Cannabis Event In New Jersey

Join the Benzinga Cannabis Market Spotlight in New Jersey on June 17th! Grow your business, raise money and capitalize on the booming NJ recreational market. Don’t miss this must-attend event in New Brunswick. Secure your tickets now. Very few spots are left. Use the code "JAVIER20" for 20% off!